Comparison of First- and Second-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes Based on the Hemoglobin A1c Level

Table 2

Clinical outcomes by Kaplan–Meier analysis and Cox proportional hazard ratio analysis at 2 years.

Outcomes	1G-DES	2G-DES	Log-rank	Hazard ratio (95% CI)	value
All patients
POCOs	100 (13.9)	353 (8.8)	<0.001	1.616 (1.294–2.017)	<0.001
All-cause death	43 (5.9)	171 (4.2)	0.035	1.431 (1.024–1.999)	0.036
Cardiac death	34 (4.7)	129 (3.1)	0.030	1.514 (1.037–2.209)	0.032
Re-MI	9 (1.3)	79 (2.0)	0.192	1.576 (0.791–3.141)	0.196
Death or MI	52 (7.2)	244 (6.0)	0.224	1.204 (0.892–1.624)	0.225
^aAny disease revascularization	58 (8.4)	138 (3.6)	<0.001	2.383 (1.752–3.238)	<0.001
Stent thrombosis (probable or definite)	14 (1.9)	28 (0.7)	0.001	2.956 (1.556–5.615)	0.001
Acute	1 (0.1)	2 (0.0)	0.355	2.941 (0.267–32.44)	0.378
Subacute	4 (0.6)	13 (0.3)	0.290	1.814 (0.591–5.563)	0.298
Late	7 (1.0)	10 (0.2)	0.002	4.146 (1.578–10.89)	0.004
Very late	2 (0.3)	3 (0.1)	0.103	3.967 (0.663–23.74)	0.131
Propensity score-matched patients
POCOs	94 (13.5)	64 (9.5)	0.017	1.467 (1.068–2.015)	0.018
All-cause death	42 (6.0)	36 (5.3)	0.541	1.149 (0.736–1.793)	0.541
Cardiac death	33 (4.8)	25 (3.7)	0.317	1.303 (0.775–2.191)	0.319
Re-MI	8 (1.2)	8 (1.2)	0.971	1.019 (0.382–2.714)	0.971
Death or MI	50 (7.2)	44 (6.5)	0.588	1.118 (0.746–1.677)	0.588
^aAny disease revascularization	54 (8.2)	24 (3.7)	0.001	2.259 (1.397–3.654)	0.001
Stent thrombosis (probable or definite)	13 (1.9)	3 (0.4)	0.012	4.361 (1.243–15.30)	0.021
Acute	1 (0.1)	0 (0.0)	0.317	—	—
Subacute	3 (0.4)	1 (0.1)	0.316	3.006 (0.313–28.90)	0.340
Late	7 (1.0)	2 (0.3)	0.093	3.526 (0.733–16.98)	0.116
Very late	2 (0.3)	0 (0.0)	0.155	—	—

1G: first-generation; 2G: second-generation; DES: drug-eluting stent; HR: hazard ratio; CI: confidence interval; POCOs: patient-oriented composite outcomes; Re-MI: recurrent myocardial infarction. ^aAny disease revascularization was composed of target lesion revascularization, target vessel revascularization, and nontarget vessel revascularization.